PTEN and glioblastoma: We found that GBM patients with PIP4K2A wild-type exhibited significantly favorable survival outcomes compared with the patients with PIP4K2A deletion in PTEN-deleted cohorts, which suggests clinical relativity (Fig. 6, L and M).